Role of Famotidine in the Clinical Improvement of COVID-19 Patients.
Status:
Completed
Trial end date:
2021-04-15
Target enrollment:
Participant gender:
Summary
This study is aimed to investigate the effect of Famotidine in the clinical recovery of
COVID-19 patients. COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there
is no specific medication against it. Like other countries of the world, Besides antiviral
drugs, immunosuppressive agents, and symptomatic therapy like H2 receptor blocker FAMOTIDINE
came to the limelight due to its role in reducing the symptoms of COVID-19 patients. The
study will include COVID-19 participants to confirm by RT PCR or an HRCT chest. Detail
history of each participant with comorbidity will be taken and will be examined carefully.
The hospitalized patients admitted to the HDU/ICU units will be enrolled in this study.
Critically ill patients who require ventilator support will not be included in this study.
The outcome of the Famotidine treatment will be evaluated and compared with a control group.
Phase:
Phase 3
Details
Lead Sponsor:
Chattogram General Hospital
Collaborators:
First Affiliated Hospital Xi'an Jiaotong University M Abdur Rahim Medical College and Hospital